Though some studies show benefit, high-quality data demonstrating the efficacy of betahistine in the treatment of MD is absent.
![](https://www.enttoday.org/wp-content/uploads/2016/09/ENT_0916_pg6a-150x150.png)
Though some studies show benefit, high-quality data demonstrating the efficacy of betahistine in the treatment of MD is absent.
Current options for hearing rehabilitation offer different advantages to patients with single-sided deafness, and no single modality is clearly superior to the others.
Though the evidence is encouraging, clear causal linkage between hearing loss and cognition has not been established.
Many patients who would likely benefit from implantation are never referred due to poor regional access, and, perhaps most importantly, lack of established CIE referral guidelines.
Sterotactic radiosurgery (SRS) for the treatment of VS can be associated with increased balance symptoms, often within the first six months after treatment.
Cost-effectiveness varies between adults and children.
There is evidence that steroid use may be beneficial to improve hearing preservation.
Betahistine is widely used in Europe and the rest of the world in the treatment of Ménière’s disease.
Literature review does not support routine use of tomography (CT) prior to planned primary stapedotomy in patients with adult-onset CHL/MHL.
Newer studies assess the effect of cochlear implants on independent risk factors for dementia associated with hearing loss, including cognition, depression, and physical activity.